Cancer Prevention in Women With a BRCA Mutation

Breast Cancer Clinical Trial

Official title: Cancer Prevention in Women With a BRCA Mutation: A Follow-up Genetic Counselling Intervention

Status Recruiting

Clinical Trial Summary

This study aims to develop a follow-up telephone-based genetic counselling (FTGC) intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counseling in the past. Typically, when women undergo genetic testing, they receive standard genetic counselling prior to testing in order to fully understand the procedure and associated implications. If a woman's genetic test results are positive for a mutation, cancer prevention options are then discussed with a counsellor. However, in Canada, there is currently no formal follow-up counselling for women with a BRCA mutation to provide ongoing guidance and support about latest risk reduction strategies. Standard care relies on women making contact for any follow-up questions or concerns they may have. As a result, these women might not have the most current information regarding genetic risk assessment and prevention options. Therefore, individuals are being asked to participate in this study to aid research about the efficacy of FTGC in women with a BRCA mutation.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• BRCA1 Gene Mutation
• BRCA2 Gene Mutation
• Breast Cancer
• Ovarian Cancer
• Ovarian Neoplasms

• NCT number: NCT02225015
• Study type: Interventional
• Source: Women's College Hospital
• Contact: Sophia Virani
• Phone: 416-351-3800
• Email: sophia.virani@wchospital.ca
• Status: Recruiting
• Phase: Phase 1
• Start date: January 2015
• Completion date: June 2019